Biocon is currently trading at Rs. 518.00, up by 71.45 points or 16.00% from its previous closing of Rs. 446.55 on the BSE.
The scrip opened at Rs. 491.20 and has touched a high and low of Rs. 519.50 and Rs. 483.00 respectively. So far 2364003 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 519.50 on 04-Dec-2017 and a 52 week low of Rs. 293.74 on 27-Dec-2016.
Last one week high and low of the scrip stood at Rs. 519.50 and Rs. 410.80 respectively. The current market cap of the company is Rs. 30270.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 19.23% and 20.10% respectively.
Mylan N.V. and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Applicat- ions (MAA) for proposed biosimilar trastuzumab and proposed biosimilar pegfilgrastim. Trastuzumab is used to treat certain HER2-positive breast and gastric cancers. Pegfilgrastim is used to reduce the duration of neutropenia (low count of neutrophils, a type of white blood cells) and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer.
EMA acceptance of the submissions follows an earlier withdrawal of both applications in response to an audit conducted by the European inspecting authority of Biocon’s drug product facility. Biocon has completed the Corrective and Preventive Actions (CAPAs) outlined as a result of the audit observations. The CAPAs will be confirmed during re-inspection, which will be completed as part of the regulatory review process.
Good Manufacturing Practice (GMP) compliance certificates for Biocon’s two drug substance manufacturing facilities in Bangalore have been issued previously. Approval of these sites is key in the development and approval process as drug substance manufacture is core to the production of the actual biologic product in GMP compliance.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1486.35 |
| Dr. Reddys Lab | 5962.50 |
| Cipla | 1400.00 |
| Zydus Lifesciences | 933.40 |
| Lupin | 1580.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
